Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine

被引：0
|
作者：
Hersh, E.
Weber, J.
Powderly, J.
Pavlik, A.
Nichol, G.
Yellin, M.
Cranmer, L.
Urba, W.
O'Day, S.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Comprehens Melanoma Res Ctr, Tampa, FL USA
[3] Carolina BioOncol Inst, Hunterville, NC USA
[4] NYU, Med Ctr, New York, NY 10016 USA
[5] Medarex Inc, Bloomsbury, NJ USA
[6] Providence Portland Med Ctr, Portland, OR USA
[7] Angeles Clin, Res Inst, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9038
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long-term survival in patients with advanced immunodeficiency
    Chene, G
    Easterbrook, PJ
    Juszczak, E
    Yu, LM
    Pocock, SJ
    Gazzard, BG
    AIDS, 1997, 11 (02) : 209 - 216
  • [42] Long-term survival of stage IV melanoma patients treated with a polyvalent, shed antigen, melanoma vaccine
    Laky, D
    Shapiro, RL
    Harris, MN
    Roses, DF
    Jacquotte, AZ
    Reynolds, SR
    Bystryn, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (01) : 240 - 240
  • [43] Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
    Koller, Kristian M.
    Mackley, Heath B.
    Liu, Jason
    Wagner, Henry
    Talamo, Giampaolo
    Schell, Todd D.
    Pameijer, Colette
    Neves, Rogerio I.
    Anderson, Bryan
    Kokolus, Kathleen M.
    Mallon, Carol A.
    Drabick, Joseph J.
    CANCER BIOLOGY & THERAPY, 2017, 18 (01) : 36 - 42
  • [44] CONDITIONAL SURVIVAL (CS) PROBABILITIES FOR ADVANCED MELANOMA PATIENTS TREATED WITH IPILIMUMAB: MODEL BASED ANALYSIS
    Lee, D.
    Kotapati, S.
    Gueron, B.
    Bapat, U.
    Batty, A. J.
    VALUE IN HEALTH, 2013, 16 (07) : A398 - A398
  • [45] Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab
    Postow, Michael A.
    Chasalow, Scott D.
    Kuk, Deborah
    Panageas, Katherine S.
    Cheng, Michael L.
    Yuan, Jianda
    Wolchok, Jedd D.
    MELANOMA RESEARCH, 2020, 30 (01) : 71 - 75
  • [46] Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.
    Foppen, Marnix Heimen Geukes
    Jordanova, Ekatarina S.
    Van Thienen, Johannes V.
    Punt, Simone
    Van de Wiel, Bart
    Haanen, John B. A. G.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
    O'Day, S.
    Weber, J.
    Lebbe, C.
    Maio, M.
    Pehamberger, H.
    Harmankaya, K.
    Siegel, J.
    Hoos, A.
    Humphrey, R.
    Wolchok, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A Case of Long-term Survival of Advanced Paratesticular Rhabdomyosarcoma Treated With a Multimodal Therapy Including a Combination of Cyclophosphamide, Vincristine, Doxorubicin and Dacarbazine
    Isono, Makoto
    Sato, Akinori
    Asano, Tomohiko
    UROLOGY CASE REPORTS, 2016, 7 : 3 - 6
  • [49] Ipilimumab prolongs survival in advanced melanoma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E481 - E481
  • [50] Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
    Georgina V Long
    Victoria Atkinson
    Paolo A Ascierto
    Benjamin Brady
    Caroline Dutriaux
    Michele Maio
    Laurent Mortier
    Jessica C. Hassel
    Piotr Rutkowski
    Catriona McNeil
    Ewa Kalinka-Warzocha
    Kerry J. Savage
    Micaela Hernberg
    Celeste Lebbé
    Julie Charles
    Catalin Mihalcioiu
    Vanna Chiarion-Sileni
    Cornelia Mauch
    Henrik Schmidt
    Dirk Schadendorf
    Helen Gogas
    Christine Horak
    Brian Sharkey
    Ian M. Waxman
    Caroline Robert
    Journal of Translational Medicine, 13 (Suppl 1)
12345